

Press Release

Contact:

INVESTOR RELATIONS
Ashish Girotra
ashishg@drreddys.com
(Ph: +1 6093756145)

MEDIA RELATIONS
Lori McCreary
lmccreary@drreddys.com
(Ph: +1 6093752995)

107 College Road East
Princeton, NJ 08540
www.promiuspharma.com

Focus on psoriasis; Promius Pharma announces 4 posters regarding SERNIVO® (betamethasone dipropionate) Spray, 0.05% at Fall Clinical Dermatology Conference®

Princeton, NJ, USA. October 13, 2017 – Promius Pharma LLC announced today that 4 posters regarding psoriasis treatment SERNIVO® (betamethasone dipropionate) Spray, 0.05% will be presented at the Fall Clinical Dermatology Conference® in Las Vegas, NV, October 12-15, 2017.

The posters represent Promius Pharma's commitment to dermatological science pertaining to psoriasis. "The results of this research provide compelling insights into the treatment of moderate psoriasis, including a novel steroid vehicle with an early onset of action," said author Dr Leon Kircik of Icahn School of Medicine at Mount Sinai. "SERNIVO has continued to demonstrate its effectiveness as a treatment option."

Indications and Usage

SERNIVO Spray is indicated for the treatment of mild-to-moderate plaque psoriasis in patients 18 years of age or older.

IMPORTANT SAFETY INFORMATION

SERNIVO Spray can produce reversible hypothalamic-pituitary-adrenal (HPA) axis suppression with the potential for glucocorticosteroid insufficiency. Systemic effects of topical corticosteroids may also manifest as Cushing's syndrome, hyperglycemia or unmasking of latent diabetes mellitus, and glucosuria. These events are rare and generally occur after prolonged exposure to larger than recommended doses, particularly with high-potency topical corticosteroids. Do not use if atrophy is present at the treatment site. Do not use with occlusive dressings. Avoid use on the face, scalp, axilla, groin or other intertriginous areas. Use of SERNIVO Spray is not recommended in pediatric patients as they are more susceptible to systemic toxicity. Allergic contact dermatitis may occur. The most common adverse reactions (≥1%) were application site pruritus, burning and/or stinging, pain, and atrophy. Local reactions and skin atrophy are more likely to occur with occlusive use, prolonged use, or use of higher potency corticosteroids. These are not all the possible side effects of SERNIVO Spray. Please see [Full Prescribing Information](#).

About Promius Pharma LLC

Promius Pharma is a wholly owned subsidiary of Dr. Reddy's Laboratories, one of the largest and most respected pharmaceutical companies in the world. With a robust commercial infrastructure and extensive research and development capabilities through its parent company, Promius Pharma is committed to bringing new products to market that meet patients' needs in dermatology and neurology. For more information, visit www.promiuspharma.com.

Disclaimer: This press release may include statements of future expectations and other forward-looking statements that are based on the management's current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words "may", "will", "should", "expects", "plans", "intends", "anticipates", "believes", "estimates", "predicts", "potential", or "continue" and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults, currency exchange rates, interest rates, persistency levels and frequency / severity of insured loss events (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganisation, including related integration issues. The company assumes no obligation to update any information contained herein.

Press Release

Contact:

INVESTOR RELATIONS

Ashish Girotra
ashishg@drreddys.com
(Ph: +1 6093756145)

MEDIA RELATIONS

Lori McCreary
lmccreary@drreddys.com
(Ph: +1 6093752995)

107 College Road East
Princeton, NJ 08540
www.promiuspharma.com

Contact information:

Promius Pharma, LLC
107 College Rd E
Princeton, NJ 08540
www.promiuspharma.com

Media Relations:

Lori McCreary (USA)
lmccreary@drreddys.com
+1 (609) 375-2995

Copyright 2017 Promius Pharma, LLC

Disclaimer: This press release may include statements of future expectations and other forward-looking statements that are based on the management's current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words "may", "will", "should", "expects", "plans", "intends", "anticipates", "believes", "estimates", "predicts", "potential", or "continue" and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults, currency exchange rates, interest rates, persistency levels and frequency / severity of insured loss events (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganisation, including related integration issues. The company assumes no obligation to update any information contained herein.